PA
ESTA icon

PharVision Advisers’s Establishment Labs ESTA Stock Holding History

PharVision Advisers’s Portfolio ESTA Stock Details ESTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,948
Closed -$203K – 778
2025
Q3 		$203K Buy
+4,948
New +$202K 0.11% 507

Other funds holding ESTA

JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
FCM
Findell Capital Management New York $710M AUM 250.3% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

PharVision Advisers's ESTA Position: Q4 2025 in Review

PharVision Advisers sold out of Establishment Labs (ESTA) in Q4 2025, closing a stake of 4,948 shares — an estimated $203K sold.

PharVision Advisers first reported a position in ESTA in Q3 2025 and held it in 1 quarter. The position peaked at $203K in Q3 2025. 174 funds tracked by Wall St. Rank hold ESTA as of Q4 2025.

  • PharVision Advisers reported no remaining Establishment Labs position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 4,948 Establishment Labs shares in Q4 2025, an estimated $203K.
  • PharVision Advisers first reported a position in Establishment Labs in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Establishment Labs position peaked at $203K in Q3 2025.
  • 174 funds tracked by Wall St. Rank held Establishment Labs as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.